Login / Signup

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.

Esther A ZaalWei WuGerrit JansenSonja ZweegmanJacqueline CloosCelia R Berkers
Published in: Cancer & metabolism (2017)
Our findings indicate that interfering with serine metabolism may be a novel strategy to improve bortezomib therapy and identify PHGDH as a potential biomarker for BTZ resistance.
Keyphrases
  • multiple myeloma
  • protein kinase
  • newly diagnosed
  • mesenchymal stem cells
  • cell therapy